Development of the Tat-GluN2BCTM peptide as a novel therapy for acute myocardial infarction

Acute myocardial infarction (commonly known as a heart attack) is a major disease of the cardiovascular system and a leading cause of death and hospitalization in North America. It results in 7.4 million deaths globally per annum. Current clinical medications only prevent the disease but cannot cure it after a heart attack occurs. Scientific evidence suggests that DAPK1 is a vital protein that can cause heart damage during a heart attack, and I have created a compound that is able to reduce the level of DAPK1 in the heart so as to prevent heart damage. In this project, I propose to test the efficacy of this compound in various models of heart attack, which may lead to a novel therapy for this devastating disease. This proposed project will not only give me a comprehensive training in scientific research, but also help the partner organization, a Canadian biotechnology company, rapidly grow its product pipeline.

Faculty Supervisor:

Jian Ye

Student:

Wu Yang Jin

Partner:

Primary Peptides Inc

Discipline:

Medicine

Sector:

Life sciences

University:

Program: